29156 Federal Register / Vol. 87, No. 92 / Thursday, May 12, 2022 / Notices 

environment. This document presents 

statements of findings made by EPA 

during the period from February 1, 2022 

to February 28, 2022. 

III. What is the Agency’s authority for 

taking this action? 

TSCA section 5(a)(3) requires EPA to 

review a TSCA section 5(a) notice and 

make one of the following specific 

findings: 

• The chemical substance or 

significant new use presents an 

unreasonable risk of injury to health or 

the environment; 

• The information available to EPA is 

insufficient to permit a reasoned 

evaluation of the health and 

environmental effects of the chemical 

substance or significant new use; 

• The information available to EPA is 

insufficient to permit a reasoned 

evaluation of the health and 

environmental effects and the chemical 

substance or significant new use may 

present an unreasonable risk of injury to 

health or the environment; 

• The chemical substance is or will 

be produced in substantial quantities, 

and such substance either enters or may 

reasonably be anticipated to enter the 

environment in substantial quantities or 

there is or may be significant or 

substantial human exposure to the 

substance; or 

• The chemical substance or 

significant new use is not likely to 

present an unreasonable risk of injury to 

health or the environment. 

Unreasonable risk findings must be 

made without consideration of costs or 

other non-risk factors, including an 

unreasonable risk to a potentially 

exposed or susceptible subpopulation 

identified as relevant under the 

conditions of use. The term ‘‘conditions 

of use’’ is defined in TSCA section 3 to 

mean ‘‘the circumstances, as determined 

by the Administrator, under which a 

chemical substance is intended, known, 

or reasonably foreseen to be 

manufactured, processed, distributed in 

commerce, used, or disposed of.’’ 

EPA is required under TSCA section 

5(g) to publish in the Federal Register 

a statement of its findings after its 

review of a TSCA section 5(a) notice 

when EPA makes a finding that a new 

chemical substance or significant new 

use is not likely to present an 

unreasonable risk of injury to health or 

the environment. Such statements apply 

to PMNs, MCANs, and SNUNs 

submitted to EPA under TSCA section 

5. 

Anyone who plans to manufacture 

(which includes import) a new chemical 

substance for a non-exempt commercial 

purpose and any manufacturer or 

processor wishing to engage in a use of 

a chemical substance designated by EPA 

as a significant new use must submit a 

notice to EPA at least 90 days before 

commencing manufacture of the new 

chemical substance or before engaging 

in the significant new use. 

The submitter of a notice to EPA for 

which EPA has made a finding of ‘‘not 

likely to present an unreasonable risk of 

injury to health or the environment’’ 

may commence manufacture of the 

chemical substance or manufacture or 

processing for the significant new use 

notwithstanding any remaining portion 

of the applicable review period. 

IV. Statements of Administrator 

Findings Under TSCA Section 5(a)(3)(C) 

In this unit, EPA provides the 

following information (to the extent that 

such information is not claimed as 

Confidential Business Information 

(CBI)) on the PMNs, MCANs and 

SNUNs for which, during this period, 

EPA has made findings under TSCA 

section 5(a)(3)(C) that the new chemical 

substances or significant new uses are 

not likely to present an unreasonable 

risk of injury to health or the 

environment: 

• EPA case number assigned to the 

TSCA section 5(a) notice. 

• Chemical identity (generic name if 

the specific name is claimed as CBI). 

• Website link to EPA’s decision 

document describing the basis of the 

‘‘not likely to present an unreasonable 

risk’’ finding made by EPA under TSCA 

section 5(a)(3)(C). 

EPA case No. Chemical identity Website link 

J–22–0008 ........ Modified Yeast (generic) https://www.epa.gov/system/files/documents/2022-03/j-22-0008_determination_non-cbi_final.pdf. 

(Authority: 15 U.S.C. 2601 et seq.) 

Dated: May 6, 2022. 

Madison Le, 

Director, New Chemicals Division, Office of 

Pollution Prevention and Toxics. 

[FR Doc. 2022–10188 Filed 5–11–22; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL ACCOUNTING STANDARDS 

ADVISORY BOARD 

Notice of Request for Comment on an 

Exposure Draft, Omnibus 

Amendments: Technical Clarifications 

Addressing Lessee and Lessor 

Discount Rates and Sale-Leasebacks 

AGENCY: Federal Accounting Standards 

Advisory Board. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Federal Accounting Standards 

Advisory Board (FASAB) has issued an 

exposure draft of a proposed Statement 

of Federal Financial Accounting 

Standards titled Omnibus Amendments: 

Technical Clarifications Addressing 

Lessee and Lessor Discount Rates and 

Sale-leasebacks. Respondents are 

encouraged to comment on any part of 

the exposure draft. Written comments 

are requested by July 8, 2022, and 

should be sent to fasab@fasab.gov or 

Monica R. Valentine, Executive 

Director, Federal Accounting Standards 

Advisory Board, 441 G Street NW, Suite 

1155, Washington, DC 20548. 

ADDRESSES: The exposure draft is 

available on the FASAB website at 

https://www.fasab.gov/documents-forcomment/. Copies can be obtained by 

contacting FASAB at (202) 512–7350. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Monica R. Valentine, Executive 

Director, 441 G Street NW, Suite 1155, 

Washington, DC 20548, or call (202) 

512–7350. 

Authority: 31 U.S.C. 3511(d), Federal 

Advisory Committee Act, as amended (5 

U.S.C. App.). 

Dated: May 9, 2022. 

Monica R. Valentine, 

Executive Director. 

[FR Doc. 2022–10203 Filed 5–11–22; 8:45 am] 

BILLING CODE P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Meetings; Cancellation 

May 10, 2022. 

The following Commission meeting 

has been cancelled. No earlier 

announcement of the cancellation was 

possible. A Commission meeting in this 

matter will be rescheduled. 

TIME AND DATE: 10:00 a.m., Friday, May 

13, 2022. 

PLACE: The Richard V. Backley, Hearing 

Room, Room 511, 1331 Pennsylvania 

Avenue NW, Suite 504 North, 

Washington, DC 20004 (enter from F 

Street entrance). 

STATUS: Open. 


khammond on DSKJM1Z7X2PROD with NOTICES